(Q38466691)

3 September 2017

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study (English)

1 reference

3 September 2017

0 references

1 reference

1 reference

1

Brad H Rovin

1 reference

3 September 2017

Richard Furie

2

1 reference

3 September 2017

Kevin Latinis

3

1 reference

3 September 2017

R John Looney

4

1 reference

3 September 2017

Fernando C Fervenza

5

1 reference

3 September 2017

Jorge Sanchez-Guerrero

6

1 reference

3 September 2017

Romeo Maciuca

7

1 reference

3 September 2017

David Zhang

8

1 reference

3 September 2017

Jay P Garg

9

1 reference

3 September 2017

Paul Brunetta

10

1 reference

3 September 2017

Gerald Appel

11

1 reference

3 September 2017

LUNAR Investigator Group

12

1 reference

3 September 2017

9 January 2012

1 reference

3 September 2017

Arthritis & Rheumatology

1 reference

3 September 2017

64

1 reference

3 September 2017

4

1 reference

3 September 2017

1215-1226

1 reference

Updates on the treatment of lupus nephritis

3 September 2017

1 reference

Oral cyclophosphamide for lupus glomerulonephritis: an underused therapeutic option

21 January 2018

1 reference

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

21 January 2018

1 reference

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

21 January 2018

1 reference

A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus

21 January 2018

1 reference

The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets

21 January 2018

1 reference

In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis

21 January 2018

1 reference

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

Rituximab versus cyclophosphamide for ANCA-associated vasculitis

21 January 2018

1 reference

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy

21 January 2018

1 reference

B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus

21 January 2018

1 reference

B cell depletion therapy in systemic lupus erythematosus

21 January 2018

1 reference

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

21 January 2018

1 reference

B lymphocytes and lupus nephritis: new insights into pathogenesis and targeted therapies

21 January 2018

1 reference

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

21 January 2018

1 reference

Novel B cell therapeutic targets in transplantation and immune-mediated glomerular diseases

21 January 2018

1 reference

Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis

21 January 2018

1 reference

An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases

21 January 2018

1 reference

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

21 January 2018

1 reference

B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response

21 January 2018

1 reference

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

The MOS 36-ltem Short-Form Health Survey (SF-36)

21 January 2018

1 reference

Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids.

21 January 2018

1 reference

Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study

21 January 2018

1 reference

Rituximab therapy in lupus nephritis: current clinical evidence

21 January 2018

1 reference

Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry

21 January 2018

1 reference

Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases

21 January 2018

1 reference

Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients

21 January 2018

1 reference

Use of rituximab in the treatment of refractory systemic lupus erythematosus: Singapore experience

21 January 2018

1 reference

Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus

21 January 2018

1 reference

Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study

21 January 2018

1 reference

Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus

21 January 2018

1 reference

Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus

21 January 2018

1 reference

A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ART.34359

1 reference

3 September 2017

1 reference